报告公司投资评级 - 买入(维持)[4] 报告的核心观点 - 公司发布2024年三季报,前三季度营收34.14亿元(yoy+17.41%),归母净利润13.84亿元(yoy+16.59%),扣非归母净利润13.31亿元(yoy+20.80%),单三季度营收12.03亿元(yoy+15.38%),归母净利润4.80亿元(yoy+10.02%),扣非归母净利润4.63亿元(yoy+11.62%)[4] - 2024前三季度国内收入同比增长13.60%,海外市场同比增长25.16%;试剂收入同比增长17.93%,仪器收入同比增长16.27%;国内外X8仪器新增装机/销售795台,累计装机3448台,新产品T8流水线实现装机/销售30条,中大型机有序推广,新品T8推进节奏超预期[4] - 2024前三季度毛利率为72.34%,较2023年(72.96%)及2024上半年(72.61%)有所调整,预计调整国内仪器推广政策,加大产品入院进度,为集采报量夯实终端基础;同期销售费用5.22亿元(yoy+7.99%),研发费用3.27亿元(yoy+20.69%),重视长期发展,持续增加研发投入,推出T8流水线等新品[4] - 预计公司2024 - 2026年营收分别为46.79/56.60/68.00亿元,同比增速分别为19.08%/20.96%/20.13%,归母净利润分别为19.68/23.96/28.87亿元,同比增速分别为19.02%/21.76%/20.48%,当前股价对应的PE分别为27/22/18倍,基于公司在化学发光行业布局完善,试剂逐步进入放量阶段,维持“买入”评级[5] 根据相关目录分别进行总结 市场表现 - 2024年11月1日收盘价67.39元,一年内最高/最低为97.20/58.31元,总市值52,949.59百万元,流通市值45,839.19百万元,总股本785.72百万股,资产负债率8.12%,每股净资产10.33元/股[3] 盈利预测与估值 |项目|2022|2023|2024E|2025E|2026E| | ---- | ---- | ---- | ---- | ---- | ---- | |营业收入(百万元)|3,046.96|3,929.66|4,679.43|5,660.24|6,799.65| |同比增长率(%)|19.70%|28.97%|19.08%|20.96%|20.13%| |归母净利润(百万元)|1,327.92|1,653.65|1,968.16|2,396.42|2,887.26| |同比增长率(%)|36.38%|24.53%|19.02%|21.76%|20.48%| |每股收益(元/股)ROE(%)|1.69 20.75%|2.10 21.92%|2.50 22.86%|3.05 24.18%|3.67 25.16%| |市盈率(P/E)|39.87|32.02|26.90|22.10|18.34|[6] 附录:财务预测摘要 资产负债表(百万元) |会计年度|2023|2024E|2025E|2026E| | ---- | ---- | ---- | ---- | ---- | |货币资金|1,048.27|2,215.25|3,258.73|4,539.73| |应收票据及账款|631.78|665.67|805.20|967.28| |预付账款|23.09|40.75|49.29|59.21| |其他应收款|6.51|8.09|9.79|11.76| |存货|916.79|1,125.70|1,349.06|1,620.62| |其他流动资产|2,437.56|2,383.31|2,446.85|2,520.66| |流动资产总计|5,064.00|6,438.78|7,918.91|9,719.26| |长期股权投资|0.00|0.00|0.00|0.00| |固定资产|1,272.74|1,143.29|1,021.03|905.90| |在建工程|169.32|190.88|212.45|228.04| |无形资产|169.46|183.54|219.64|273.53| |长期待摊费用|156.69|130.58|104.46|78.35| |其他非流动资产|1,390.27|1,416.91|1,487.45|1,518.10| |非流动资产合计|3,158.49|3,065.21|3,045.03|3,003.92| |资产总计|8,222.49|9,503.98|10,963.94|12,723.18| |短期借款|0.00|0.00|0.00|0.00| |应付票据及账款|126.99|231.15|277.02|332.78| |其他流动负债|464.49|575.60|691.33|830.37| |流动负债合计|591.48|806.75|968.34|1,163.15| |长期借款|3.49|2.81|2.11|1.39| |其他非流动负债|83.11|83.11|83.11|83.11| |非流动负债合计|86.61|85.92|85.23|84.51| |负债合计|678.09|892.67|1,053.57|1,247.66| |股本|785.72|785.72|785.72|785.72| |资本公积|1,332.38|1,332.38|1,332.38|1,332.38| |留存收益|5,426.30|6,493.21|7,792.28|9,357.42| |归属母公司权益|7,544.40|8,611.31|9,910.38|11,475.52| |少数股东权益|0.00|0.00|0.00|0.00| |股东权益合计|7,544.40|8,611.31|9,910.38|11,475.52| |负债和股东权益合计|8,222.49|9,503.98|10,963.94|12,723.18|[7] 利润表(百万元) |会计年度|2023|2024E|2025E|2026E| | ---- | ---- | ---- | ---- | ---- | |营业收入|3,929.66|4,679.43|5,660.24|6,799.65| |营业成本|1,062.48|1,265.79|1,516.95|1,822.31| |税金及附加|15.25|18.66|22.57|27.11| |销售费用|630.31|703.41|846.76|1,001.58| |管理费用|106.96|113.33|127.46|141.56| |研发费用|366.05|437.13|517.63|617.75| |财务费用|-30.52|-5.56|-9.46|-13.56| |资产减值损失|0.00|0.00|0.00|0.00| |信用减值损失|-11.16|-7.29|-8.82|-10.60| |其他经营损益|0.00|0.00|0.00|0.00| |投资收益|74.39|62.88|62.88|62.88| |公允价值变动损益|18.55|15.62|16.74|16.92| |资产处置收益|0.05|0.26|0.26|0.26| |其他收益|34.46|41.50|41.46|41.46| |营业利润|1,895.42|2,259.65|2,750.85|3,313.82| |营业外收入|0.26|0.15|0.15|0.15| |营业外支出|2.61|2.37|2.37|2.37| |其他非经营损益|0.00|0.00|0.00|0.00| |利润总额|1,893.07|2,257.42|2,748.62|3,311.60| |所得税|239.41|289.26|352.20|424.34| |净利润|1,653.65|1,968.16|2,396.42|2,887.26| |少数股东损益|0.00|0.00|0.00|0.00| |归属母公司股东净利润|1,653.65|1,968.16|2,396.42|2,887.26| |EPS(元)|2.10|2.50|3.05|3.67|[7] 现金流量表(百万元) |会计年度|2023|2024E|2025E|2026E| | ---- | ---- | ---- | ---- | ---- | |税后经营利润|1,653.65|1,865.25|2,292.58|2,783.26| |折旧与摊销|179.20|233.79|241.47|251.63| |财务费用|-30.52|-5.56|-9.46|-13.56| |投资损失|-74.39|-62.88|-62.88|-62.88| |营运资金变动|-329.65|7.48|-275.07|-324.54| |其他经营现金流|20.00|187.62|102.11|102.11| |经营性现金净流量|1,418.29|2,225.70|2,288.76|2,736.01| |投资性现金净流量|-290.73|-162.34|-156.69|-145.74| |筹资性现金净流量|-568.61|-896.37|-1,088.59|-1,309.27| |现金流量净额|567.66|1,166.99|1,043.48|1,280.99|[7] 主要财务比率 |会计年度|2023|2024E|2025E|2026E| | ---- | ---- | ---- | ---- | ---- | |成长能力| | | | | |营收增长率|28.97%|19.08%|20.96%|20.13%| |营业利润增长率|26.06%|19.22%|21.74%|20.47%| |归母净利润增长率|24.53%|19.02%|21.76%|20.48%| |经营现金流增长率|47.37%|56.93%|2.83%|19.54%| |盈利能力| | | | | |毛利率|72.96%|72.95%|73.20%|73.20%| |净利率|42.08%|42.06%|42.34%|42.46%| |ROE|21.92%|22.86%|24.18%|25.16%| |ROA|20.11%|20.71%|21.86%|22.69%| |ROIC|47.51%|44.07%|48.31%|51.91%| |估值倍数| | | | | |P/E|32.02|26.90|22.10|18.34| |P/S|13.47|11.32|9.35|7.79| |P/B|7.02|6.15|5.34|4.61| |股息率|1.48%|1.70%|2.07%|2.50%| |EV/EBITDA|28.57|19.82|16.29|13.43|[7]
新产业:中大型仪器有序推广,国内外稳健增长